Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. - Wikidata - awgldk - TriplyDB

Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases.

Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases.

http://www.wikidata.org/entity/Q33890407

about

Phosphorylcholine-dependent cross-reactivity between dental plaque bacteria and oxidized low-density lipoproteins.Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease Endothelial cells and macrophages, partners in atherosclerotic plaque progression.Accelerated atherosclerosis in ApoE deficient lupus mouse models.The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?Effect of 1-year oral alpha-tocopherol administration on anticardiolipin antibodies in hemodialysis patients.Antiphospholipid Antibodies in Patients with Lupus Nephritis

P2860

Q33551868-5F0865A5-98E3-46A2-BF95-D0B2CC9D469C Q36399434-EFA4CF02-7E56-45CF-9DBA-E2B65C91ADEC Q36687950-448C7EA9-A9DC-48A6-96D6-236D40359E4A Q36766008-FA747BD9-4D70-4D76-BEB8-785EE92FDE6A Q37817582-1199134A-AC95-43B4-922D-D66F44C81401 Q46418949-C7857C5A-1B87-42FC-8B01-49BCF32F4C49 Q57825441-56FAB749-7B77-4044-A457-C519599F8359

P2860

Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases.

http://www.wikidata.org/entity/Q33890407

description

2000 nî lūn-bûn

@nan

2000 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մարտին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Autoantibodies to modified LDL ...... rs of cardiovascular diseases.

@ast

Autoantibodies to modified LDL ...... rs of cardiovascular diseases.

@en

type

label

Autoantibodies to modified LDL ...... rs of cardiovascular diseases.

@ast

Autoantibodies to modified LDL ...... rs of cardiovascular diseases.

@en

prefLabel

Autoantibodies to modified LDL ...... rs of cardiovascular diseases.

@ast

Autoantibodies to modified LDL ...... rs of cardiovascular diseases.

@en

P1433

Q33890407-C7FA97DE-F6B5-4AF7-BBB0-62EC48A26EEB

P1476

Q33890407-F4CB04B0-7B88-43CF-B1B2-4BE737E200C9

P2093

Q33890407-703E2A4D-E1DC-49AB-A163-3AA5FA451ACE

P2860

Q33890407-08DA6CCE-7840-4D39-A9F2-BFFF6056E4BC

Q33890407-11138B94-A860-4C9E-A555-A6D64ABA912C

Q33890407-1C40C9D3-C359-47B0-A8BB-688EA5A5F94B

Q33890407-34E3ABDF-D5D2-479D-BAD7-1BD0D9A51E86

Q33890407-40F99F93-DFA3-4812-A9C3-317F007A1022

Q33890407-538AA885-669A-412B-8388-68C8BA74E3C1

Q33890407-71944261-7026-443B-A627-A9E61ACFB71D

Q33890407-8CE5AC42-4FA8-44E6-91B0-B28EA68193CB

Q33890407-D839831E-688B-4AF1-8D14-056D07624CF6

P304

Q33890407-087D794C-841A-4BF4-AF2D-43CF035B9D18

P31

Q33890407-5ED149FB-0E80-407D-9649-A3E6567EC8C4

P356

Q33890407-49F58C7C-8B00-4E9D-B1F2-74C800C2B26C

P407

Q33890407-BE1668F1-2692-45CA-94B4-8AD29EB9160D

P433

Q33890407-E31A2ED4-1980-42D7-A663-5A31E0405509

P478

Q33890407-5ACDE640-1AE3-43B7-AF85-1E9003889455

P577

Q33890407-4465402F-CE6E-4987-9D06-AC5E8DFB74C9

P5875

Q33890407-FEA130C6-75F4-47FC-95D8-29758524C78D

P698

Q33890407-A07E7844-1751-444E-BF5F-4BAD1F74A20B

P921

Q33890407-68B6B38E-D008-4A46-8470-9DFC3755D1CD

Q33890407-D8DC4A43-6CAD-430F-904D-2EF6399C74AB

P356

J.1365-2796.2000.00657.X

P1433

Journal of Internal Medicine

P1476

Autoantibodies to modified LDL ...... rs of cardiovascular diseases.

@en

P2093

Vaarala O

http://www.w3.org/2001/XMLSchema#string

P2860

Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome.

Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression.

The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor.

Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke.

Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes.

Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis.

IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.

Relation of inflammation to vascular function in patients with coronary heart disease

P304

381-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2796.2000.00657.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

247

http://www.w3.org/2001/XMLSchema#string

P577

2000-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12554975

http://www.w3.org/2001/XMLSchema#string

P698

10762455

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease